The
#AIEye: Veritone’s (NasdaqGM: $VERI) aiWARE Receives FedRAMP Approval and Viome
Collaborating with Helomics (NasdaqCM: $AIPT) to Study Cancer with #AI
AI-Based
Chatbot Market to Reach $2.2 Billion by 2024
Point Roberts WA, Vancouver BC – March 25, 2019 – Investorideas.com (www.investorideas.com), a global investor news source covering
Artificial Intelligence (AI) brings you today’s edition of The AI Eye- watching stock news, deal tracker and advancements in artificial
intelligence.
Listen
to today’s podcast:
Read
this in full at https://www.investorideas.com/news/2019/artificial-intelligence/03251VERI-aiWARE-Viome-Helomics.asp
Today’s
Column- The
AI Eye- Watching stock news, deal tracker and advancements
in artificial intelligence
AI-Based
Chatbot Market to Reach $2.2 Billion by 2024
A new report from Research and Markets indicates that the
AI-based chatbot market will reach $2.2 billion globally by 2024. An excerpt
from the report summary reads:
Artificial Intelligence (AI) enabled
chatbots are taking Customer Relationship Management (CRM) to a new level as
business-to-business, business-to-consumer, and consumer-to-business
communications is both automated and improved by way of push and pull of the
right information at the right time. Chatbots also provide benefits to
customers as both existing clients and prospects enjoy the freedom to interact
on their own terms. Our research indicates that over 50% of customer queries
may be managed today via AI-based chatbots.
Veritone’s
aiWARE Receives FedRAMP Approval and Viome Collaborating with Helomics to Study
Cancer with AI
Stocks
discussed: (NasdaqGM:VERI) (NasdaqCM:AIPT)
Veritone, Inc. (NasdaqGM:VERI) has received Federal Risk and Authorization
Management Program (FedRAMP) Authorization for its aiWARE platform. aiWARE is a
government platform which “orchestrates an expanding ecosystem of machine
learning models to transform audio, video and other data sources into
actionable intelligence”. Ryan Steelberg, president of Veritone, said:
“Achieving a FedRAMP Authorization is a
huge milestone for Veritone and validates our AI platform as a viable and
secure option for federal agencies to leverage artificial intelligence to
accomplish their missions more efficiently and effectively. Because our aiWARE
Government platform fulfilled the rigorous security requirements to achieve a
FedRAMP Authorization, individual agencies can now expedite the procurement and
use of our AI offerings.”
Health tech firm Viome has
announced a collaboration with Precision
Therapeutics Inc. (NasdaqCM:AIPT) company Helomics to study the
link between the gut microbiome and ovarian cancer. The study will see Viome’s
proprietary microbiome analysis platform and artificial intelligence (AI)
platform. Gerald Vardzel, President and CEO of Helomics Corporation, said:
"Helomics
pioneered using knowledge gained from drug response and genomic profiling of
the patient's living tumor to help individualize ovarian cancer therapy. The
collaboration with Viome is groundbreaking, generating data from the microbiome
combined with our existing data and using our respective AI platforms, to offer
an innovative, holistic and personalized approach to helping oncologists choose
the best treatment options for patients with ovarian cancer.”
Sam
Mowers, Investorideas.com
For
a list of artificial intelligence stocks on Investorideas.com visit
here
or become an Investor Ideas member
About Investorideas.com - News that
Inspires Big Investing Ideas Investorideas.com is a
recognized news source publishing third party news and press releases plus we
create original financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts
and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto
Corner and Podcast, Play by Play sports and stock news column, Investor
Ideas #Potcasts #Cannabis News and Stocks on the Move
podcast and column, Cleantech and
Climate Change Podcast and the AI Eye Podcast and column covering
developments in AI.
The
Investorideas.com podcasts are also available on iTunes, Spotify, Tunein, Stitcher, Spreaker.com,
iHeartRadio and Google Play Music.
Visit
the Podcast page at Investorideas.com:
Disclaimer/Disclosure:
Investorideas.com is a digital publisher of third party sourced news, articles
and equity research as well as creates original content, including video,
interviews and articles. Original content created by investorideas is protected
by copyright laws other than syndication rights. Our site does not make
recommendations for purchases or sale of stocks, services or products. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investment involves risk and possible loss of
investment. This site is currently compensated for news publication and
distribution, social media and marketing, contents creation and more. Contact
each company directly regarding content and press release questions. Disclosure
is posted for each compensated news release, content published /created if
required but otherwise the news was not compensated for and was published for
the sole interest of our readers and followers. Disclosure: More disclaimer
info: shttps://www.investorideas.com/About/Disclaimer.asp ,
Learn more about our podcast and article services and
costs https://www.investorideas.com/News-Upload/
Additional info regarding BC Residents and global
Investors: Effective September 15 2008 - all BC investors should review all OTC
and Pink sheet listed companies for adherence in new disclosure filings and
filing appropriate documents with Sedar. Read for more info: https://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations
of each country.
The
AI Eye- Watching stock news, deal tracker and
advancements in artificial intelligence is an original content brand of
Investorideas.com
Contact
Investorideas.com
800 665 0411
